10-Q - 2seventy bio, Inc. (0001860782) (Filer)

8-K - 2seventy bio, Inc. (0001860782) (Filer)

SC TO-T/A - 2seventy bio, Inc. (0001860782) (Subject)

SC 14D9/A - 2seventy bio, Inc. (0001860782) (Subject)

SC TO-T/A - 2seventy bio, Inc. (0001860782) (Subject)

SCHEDULE 13G/A - 2seventy bio, Inc. (0001860782) (Subject)

10-K/A - 2seventy bio, Inc. (0001860782) (Filer)

SC TO-T/A - 2seventy bio, Inc. (0001860782) (Subject)

SC 14D9/A - 2seventy bio, Inc. (0001860782) (Subject)

SC 14D9/A - 2seventy bio, Inc. (0001860782) (Subject)

Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 million U.S. commercial revenue in the first quarter of 2025 Ended quarter with approximately $173 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2025. "We started 2seventy with a singular focus on harnessing the power of cell therapy to deliver more time for people living with cancer," said Chip Baird, chief executive officer, 2seventy bio. "Over the pas

Entered into definitive merger agreement to be acquired by Bristol Myers Squibb at a price of $5.00 per share in an all-cash transaction; expected to close in the second quarter of 2025 Abecma generated $242 million U.S. sales in 2024 79% reduction in year-over-year net cash spend reflects continued streamlining of cost structure Ended 2024 with approximately $184 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024. "2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure a

$5.00 per share, all-cash transaction Expected to close in the second quarter of 2025, subject to customary closing conditions 2seventy bio, Inc. (NASDAQ:TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE:BMY) ("BMS") will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. The deal represents an 88% premium to the closing price of $2.66 on March 7, 2025. "A year ago, 2seventy decided to exclusively focus on unlocking the value of Abecma, with the goal of delivering more time for people living wi

2seventy bio, Inc. (NASDAQ:TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming TD Cowen 45th Annual Healthcare Conference on March 5, 2025 at 11:10 a.m. ET in Boston, Mass. A live webcast of the fireside chat will be available via the Investors and Media section of 2seventy bio's website at https://ir.2seventybio.com/. Replays will be archived on 2seventy bio's site for 30 days following the event. About 2seventy bio Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people

$242 million in U.S. Abecma sales in 2024 Approximately $184 million of cash, cash equivalents and marketable securities as of December 31, 2024 Net cash burn of $9 million in the fourth quarter of 2024; path to quarterly breakeven by the end of 2025 2seventy bio, Inc. (NASDAQ:TSVT) today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers Squibb (BMS). "We are pleased to see Abecma expansion in the third line setting and recorded U.S. revenue of $242 million in 2024, within our previously issued guidance of $240 to $250 million. Fourth quarter revenue was impacted by higher deferrals of infusions into 2025. We expec

Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in KarMMa-9 study results in over $80 million in anticipated cost savings over the next several years 24% reduction in operating expenses versus the second quarter reflects continued progress on streamlining 2seventy's cost structure; third quarter net loss of approximately $10 million Ended quarter with approximately $192 million in cash, cash equivalents, and marketable securities; expected cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for

2seventy bio, Inc. (NASDAQ:TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the financial results conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It's recommended that participants join 10 minutes prior to the event's start. Members of the management team will also be presenting at the following upcoming investor conference: Guggenheim's Inaugural H

2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study Decision results in over $80 million in anticipated cost savings for 2seventy over the next several years and accelerates path to breakeven in 2025 Expanded 3L+ label drives re-acceleration in Abecma U.S. revenues with third quarter revenue expected to grow approximately 30% from second quarter revenue of $54 million 2seventy bio, Inc. (NASDAQ:TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidom

2seventy bio, Inc. (NASDAQ:TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024 at 12:20 p.m. ET in New York. A live webcast of the fireside chat will be available via the Investors and Media section of the company's website at https://ir.2seventybio.com. Replays will be archived on the 2seventy bio website for 30 days following the events. About 2seventy bio Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to

Following regulatory approval in the earlier line setting this quarter, Abecma generated $54 million U.S. commercial revenue and saw meaningful growth in demand Recent completion of Hemophilia A and gene editing technology sale to Novo Nordisk for up to $40 million reinforces exclusive focus on Abecma with streamlined cost structure Approximately $28 million (43%) quarter-on-quarter reduction in operating expenses due to completion of sale of R&D business to Regeneron on April 1, 2024 Ended quarter with approximately $202 million cash, cash equivalents, and marketable securities; cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today re

2seventy bio, Inc. (NASDAQ:TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company's Board of Directors (the "Board"), effective immediately. Casdin Capital owns approximately 2.3% of 2seventy bio's outstanding shares as of 03/20/24. "We are pleased to welcome Eli and Charlie to the 2seventy Board," said Dan Lynch, chair of the Board of Directors. "Eli is a highly regarded, leading life sciences and healthcare investor and has a deep understanding of and history with the Company. Charlie has a track record of helping compan

Believes 2seventy Could Be Conservatively Worth ~$9 Per Share if the Company Exclusively Focuses on Its Most-Valuable Asset Abecma, Reduces Corporate Overhead and Makes Improvements to the Composition of the Management Team and Board Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (NASDAQ:TSVT) ("2seventy" or the "Company") outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the "Board"). *** December 6, 2023 2seventy bio, Inc. 60 Binney Street Cambridge, MA 02142 Attention: Board of Directors Dear Members of the Board: Engine Capital LP (together with its affiliates, "Engine" or "we"), is a meaningful shareh

O'Callaghan, a well-regarded life-science business leader with global experience and a significant track record of success, joins as part of plan to evolve Deep Genomics as a forward-integrated biopharmaceutical company Founder and current CEO Brendan Frey, Ph.D., F.R.S.C. to assume new role of chief innovation officer, remain a member of the board and bolster plans for further technology development and innovation, leveraging artificial intelligence (AI) to decode RNA biology for novel drug development Lead independent director Chip Baird appointed as chair of the board Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines

2seventy bio, Inc. (NASDAQ:TSVT) today announced the appointment of Wei Lin, M.D. to the company's Board of Directors, effective immediately. "We are thrilled to welcome Dr. Wei Lin to 2seventy's Board during an exciting time in our Company's growth," said Nick Leschly, chief kairos officer. "Wei's leadership and deep expertise in clinical development strategy for cancer immunotherapy programs will be invaluable as we innovate new treatments to provide more time to patients and families living with cancer." "I am excited to join 2seventy's Board of Directors and contribute my experience in clinical development," said Wei Lin, M.D. "Unleashing the power of the T cell is a truly inspiring s

CAMBRIDGE, Mass., March 1, 2023 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel immuno-therapeutics targeting the T cell receptor (TCR) Vβ to selectively activate the right T cell subsets to fight cancer, today announced the appointment of Kevin Chin, M.D., M.S., as Chief Medical Officer. Dr. Chin is a seasoned oncology clinical development expert in T cell directed immunotherapies with a proven track record of developing successful programs from research to regulatory approvals. In his role, Dr. Chin will be responsible for the progress of the company's clinical portfolio starting with the recently announced START-001 Phase 1/2 clinical trial of Marengo's immuno-oncol

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. "I am delighted to welcome Cintia to our leadership team. She brings extensive commercial experience, including in cell and gene therapy, that will be key as we prepare to submit our first BLA for afami-cel this year, and build our commercial capabilities to support the launch of this initial product and future next-gen cell therapies within our MAGE-A4 franchise. Her fresh perspective and leadership abilities will supp

Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 million U.S. commercial revenue in the first quarter of 2025 Ended quarter with approximately $173 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2025. "We started 2seventy with a singular focus on harnessing the power of cell therapy to deliver more time for people living with cancer," said Chip Baird, chief executive officer, 2seventy bio. "Over the pas

Entered into definitive merger agreement to be acquired by Bristol Myers Squibb at a price of $5.00 per share in an all-cash transaction; expected to close in the second quarter of 2025 Abecma generated $242 million U.S. sales in 2024 79% reduction in year-over-year net cash spend reflects continued streamlining of cost structure Ended 2024 with approximately $184 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024. "2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure a

Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in KarMMa-9 study results in over $80 million in anticipated cost savings over the next several years 24% reduction in operating expenses versus the second quarter reflects continued progress on streamlining 2seventy's cost structure; third quarter net loss of approximately $10 million Ended quarter with approximately $192 million in cash, cash equivalents, and marketable securities; expected cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for

2seventy bio, Inc. (NASDAQ:TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the financial results conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It's recommended that participants join 10 minutes prior to the event's start. Members of the management team will also be presenting at the following upcoming investor conference: Guggenheim's Inaugural H

Following regulatory approval in the earlier line setting this quarter, Abecma generated $54 million U.S. commercial revenue and saw meaningful growth in demand Recent completion of Hemophilia A and gene editing technology sale to Novo Nordisk for up to $40 million reinforces exclusive focus on Abecma with streamlined cost structure Approximately $28 million (43%) quarter-on-quarter reduction in operating expenses due to completion of sale of R&D business to Regeneron on April 1, 2024 Ended quarter with approximately $202 million cash, cash equivalents, and marketable securities; cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today re

2seventy bio, Inc. (NASDAQ:TSVT) will announce its second quarter 2024 financial results on Wednesday, August 7, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It is recommended that participants join 10 minutes prior to the event's start. A replay of the call will be available on the 2seventy bio website following the completion of the call. About 2seventy bio Our name, 2seventy

U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy; Commercial Launch Underway Completion of R&D Pipeline Divestiture to Regeneron Sets Company on Track to Focus Exclusively on Development and Commercialization of Abecma with Streamlined Cost Structure Abecma generated $52 million U.S. commercial revenue in the first quarter of 2024 Ended quarter with $181.4 million cash, cash equivalents, and marketable securities; cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2024.

2seventy bio, Inc. (NASDAQ:TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It is recommended that participants join 10 minutes prior to the event's start. A replay of the call will be available on the 2seventy bio website following the completion of the call. About 2seventy bio Our name, 2seventy bi

New strategic path forward as Abecma-focused company announced in January 2024; on track to close Asset Sale of R&D pipeline to Regeneron in the first half of 2024 U.S. Food and Drug Administration Oncologic Drugs Advisory Committee scheduled for March 15, 2024, to review data supporting the supplemental Biologics License Application for Abecma® (idecabtagene vicleucel) for triple-class exposed relapsed or refractory multiple myeloma Abecma generated $56 million U.S. commercial revenue in the fourth quarter of 2023 and $358 million for the full year, shared equally with Bristol Myers Squibb Ended quarter with $221.8 million cash, cash equivalents, and marketable securities; cash runwa

2seventy bio, Inc. (NASDAQ:TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Members of the management team will also be presenting at the following upcoming investor conferences: TD Cowen 44th Annual Healthcare Conference in Boston, MA on Wednesday, March 6, 2024 at 2:10 p.m. ET Leerink Partners Global Biopharma Conference in Miami, FL on Wednesday, March 13 at 8:00 a.m. ET Live webcasts of the investor conference presentations will be available via the Investors and Media section of 2seventy bio's website at https://ir.2seventybio.com/. Replays will be archived on 2s